

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Epione[®] Surgical Navigation System obtained official registration approval by the China NMPA

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 16 August 2023, the Epione[®] Surgical Navigation System, (“**Epione[®]**” or the “**Product**”) introduced by Dongguan LifeTech-Quantum Medical Technology Co., Ltd. (joint venture company and controlled by the Group) obtained official registration approval by the China National Medical Products Administration (“**NMPA**”).

The Product is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of rigid straight instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedure. It can provide stable, accurate, and repeatable instrument navigation, which can simplify the operation and reduce the operative risk. Epione[®] is designed to improve operation efficiency, reduce needle adjustments, reduce radiation dose, and reduce the probability of complications, which has great value especially for the treatment of complex lesions. In September 2021, Epione[®] obtained the European CE certification, and it was approved by the US Food and Drug Administration (the “**FDA**”) for the treatment of liver cancer in March 2022, and also received approval by the FDA for the extension of application scope to all abdominal tumors in May 2023. In August 2023, Epione[®] obtained registration approval by the NMPA, with indications covering all abdominal organs.

Epione[®] is an open robotic solution that is compatible with various treatment methods such as tumor ablation, biopsy, and particle implantation. For tumor ablation surgery, the design of Epione[®] allows doctors to choose different ablative technologies (radiofrequency, microwave, cryoablation, irreversible electroporation) so that they can determine the right therapy for each individual. The goal of Epione[®] is to dramatically ease multiple probe procedures, which will make the treatment of large tumors more predictable. Additionally, the arm of Epione[®] offers 6 degrees of freedom and unprecedented dexterity to access difficult trajectories when targeting abdominal tumors.

Epione[®] has gradually been applied in clinical treatment in Europe and the United States. It is expected that over 4 million patients worldwide will be able to benefit from Epione[®] treatment. The Group will continue with independent innovation, and work with industry experts to advance the development and marketing of innovative medical device products to benefit a large number of patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 21 August 2023

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.